Cargando…
Variant constraint by mRNA vaccines
The currently licensed mRNA vaccines for SARS-CoV-2 can elicit cross-neutralizing antibodies against B.1.351 variants of the virus, but are less potent against these variants.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034506/ https://www.ncbi.nlm.nih.gov/pubmed/33837367 http://dx.doi.org/10.1038/s41577-021-00548-5 |